Orphan Synergy Europe - Pharma Aktie
| 3,69EUR | 0,01EUR | 0,16% |
WKN DE: A14QXP / ISIN: FR0012127173
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 61 | 67 | 55 | 64 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,43 | 0,27 | 0,04 | 1,09 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 44 | 37 | 30 | 70 | 0 |
| Summe Anlagevermögen | 57 | 54 | 51 | 54 | 0 |
| Summe Aktiva | 102 | 92 | 82 | 124 | 0 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 54 | 59 | 59 | 60 | 0 |
| Summe Eigenkapital | 48 | 33 | 23 | 63 | 0 |
| Summe Passiva | 102 | 92 | 82 | 124 | 0 |
Adresse
| 22, Boulevard Benoni Goullin, 44000 Nantes | |
| Telefon | +33 (2) 28-29-10-10 |
| Internet | http://www.ose-immuno.com |
Management
|
Anne-Laure Autret-Cornet
Director, Chief Administrative Officer |
|
Aurore Morello
Chief Scientific Officer |
|
Brigitte Dreno
Independent Director |
|
Cécile Nguyen-Cluzel
Independent Director |
|
Eric Jean Marie Leire
Independent Director |
|
Fiona Olivier
Chief Corporate Affairs Officer |
|
Jean Jacques Mention
Chief Business Officer |
|
Jean-Pascal Conduzorgues
Chief Manufacturing Officer |
|
Laurence de Schoulepnikoff
Chief Operating & Business Officer |
|
Linda Lebon
Chief Regulatory Officer |
|
Marc Dechamps
Independent Director |
|
Marc Le Bozec
Chief Executive Officer |
|
Markus Goebel
Independent Director |
|
Markus J. Cappel
Chairman |
|
Martine Ortin George
Independent Director |
|
Maryvonne Hiance
Vice Chairman & Public Affairs Director |
|
Silvia Comis
Head-Clinical Development |
|
Sonya Montgomery
Chief Development Officer |
|
Thomas Gidoin
Chief Financial Officer & Deputy CEO |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.